Related Experiment Video
Updated: Nov 22, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Study on Targeting Relationship Between miR-320b and FGD5-AS1 and Its Effect on Biological Function of Osteosarcoma
Qing-Hua Song1, Ming-Jun Guo1, Jun-Shui Zheng2
1Department of Repair and Reconstruction Surgery, The First Hospital of Ningbo, Ningbo, Zhejiang Province 315000, People's Republic of China.
Objective:
To probe into the expression of FGD5-AS1 in osteosarcoma and its relationship with miR-320b.
Methods:
The tissue and serum samples of 97 patients with osteosarcoma were collected, and the serum samples of 100 healthy subjects who concurrently underwent physical examination were selected as the control. FGD5-AS1 expression in tissues and serum was detected, and osteosarcoma cells were transfected to measure cell behaviors such as proliferation, invasion and apoptosis.
Results:
FGD5-AS1 was highly expressed in osteosarcoma, and its elevated expression indicated poor survival of patients. Serum FGD5-AS1 was related to tumor size and clinical stage and could be used for the diagnosis of osteosarcoma. The study of osteosarcoma cell lines U2OS and SaOS-2 showed that after inhibiting FGD5-AS1, the viability and invasion capacity of osteosarcoma cells decreased statistically compared with the control group (CG), while the apoptosis ability could be improved by further regulating apoptotic proteins (P<0.05). Detection of EMT-related proteins identified that E-cadherin increased while N-cadherin decreased significantly after FGD5-AS1 inhibition (P<0.05). Correlation analysis revealed a negative correlation between miR-320b and FGD5-AS1 (r = -0.410, P<0.001). Overexpression of miR-320b significantly inhibited cell viability, invasion and EMT ability, and increased the apoptosis rate, while inhibiting miR-320b expression produced the opposite results. The targeting relationship between miR-320b and FGD5-AS1 was confirmed through the biological prediction website, luciferase assay and RNA binding protein immunoprecipitation (RIP) assay. Inhibition of miR-320b could reverse the regulatory effect of FGD5-AS1 knockdown on osteosarcoma cells.
Conclusion:
FGD5-AS1 is highly expressed in osteosarcoma and is involved in the biological procession of osteosarcoma by targeting miR-320b.
Insights
FGD5-AS1 is highly expressed in osteosarcoma, impacting patient survival. This long non-coding RNA targets miR-320b, influencing cancer cell proliferation, invasion, and apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma is a primary bone malignancy with significant mortality.
- Long non-coding RNAs (lncRNAs) play crucial roles in cancer development.
- FGD5-AS1's role in osteosarcoma remains largely unexplored.
Purpose of the Study:
- To investigate the expression levels of FGD5-AS1 in osteosarcoma.
- To explore the correlation between FGD5-AS1 and miR-320b in osteosarcoma.
- To elucidate the functional role of FGD5-AS1 in osteosarcoma cell behavior.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) to measure FGD5-AS1 expression in patient tissues and serum.
- Cell transfection assays to assess the impact of FGD5-AS1 inhibition on osteosarcoma cell proliferation, invasion, and apoptosis.
- Western blot analysis to detect epithelial-mesenchymal transition (EMT)-related proteins.
- Bioinformatic predictions, luciferase reporter assays, and RNA immunoprecipitation (RIP) assays to confirm the interaction between FGD5-AS1 and miR-320b.
Main Results:
- FGD5-AS1 was significantly upregulated in osteosarcoma tissues and serum, correlating with poor patient survival, tumor size, and clinical stage.
- Inhibition of FGD5-AS1 suppressed osteosarcoma cell viability and invasion while promoting apoptosis and increasing E-cadherin expression, decreasing N-cadherin.
- A negative correlation was observed between FGD5-AS1 and miR-320b.
- miR-320b overexpression mimicked the effects of FGD5-AS1 inhibition, and inhibition of miR-320b reversed these effects, confirming their regulatory relationship.
Conclusions:
- FGD5-AS1 is oncogenic in osteosarcoma, promoting cell proliferation and invasion via targeting miR-320b.
- Serum FGD5-AS1 may serve as a diagnostic biomarker for osteosarcoma.
- Targeting the FGD5-AS1/miR-320b axis presents a potential therapeutic strategy for osteosarcoma.
